NF Central plains
DEDICATED TO AWARENESS, EDUCATION, AND SUPPORT FOR THOSE AFFECTED BY NEUROFIBROMATOSIS
Several investigations are being conducted to effect change in the limited therapy options available to NF2 patients. One such study is being led by Dr. Vijaya Ramesh at Massachusetts General Hospital, and is funded by CureNF2. One of the most difficult obstacles in slowing or even stopping the growth of NF tumors is that there are three different types, all arising from different types of cells in the brain and spinal cord. It is hypothesized that if the factors contributing to the growth of NF2 tumors could be blocked early on, tumor growth could be halted. Dr. Ramesh will study both single and combination chemotherapies as signal blockers in cell lines.
Another investigation is being led by NF2 BioSolutions, a nonprofit organization focused on using gene therapy and immunotherapy to treat and cure NF2. One approach NF2 BioSolutions is pursuing uses a viral vector to introduce a “suicide” gene into NF2 tumor cells to induce the cells to die, a process called apoptosis. Another approach introduces a new and functional copy of the NF2 gene to replace the protein missing in individuals with NF2 (Merlin).
9218 Metcalf, Ste 335
Overland Park, KS 66212